HealthEquity (NASDAQ:HQY) Upgraded to “Buy” at Wall Street Zen

HealthEquity (NASDAQ:HQY) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the stock. BTIG Research reaffirmed a “buy” rating and set a $130.00 price objective on shares of HealthEquity in a research report on Thursday, December 4th. Barrington Research restated an “outperform” rating and set a $125.00 price target on shares of HealthEquity in a report on Thursday, December 4th. JPMorgan Chase & Co. lifted their price objective on shares of HealthEquity from $126.00 to $129.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. KeyCorp decreased their price objective on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $120.00 target price on shares of HealthEquity in a report on Friday, December 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $120.27.

HealthEquity Price Performance

HQY opened at $91.07 on Friday. The stock has a fifty day moving average price of $96.92 and a 200 day moving average price of $95.45. The company has a current ratio of 4.13, a quick ratio of 4.13 and a debt-to-equity ratio of 0.46. HealthEquity has a 1 year low of $74.07 and a 1 year high of $116.65. The stock has a market cap of $7.78 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 1.32 and a beta of 0.20.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $322.16 million for the quarter, compared to analyst estimates of $320.92 million. HealthEquity had a return on equity of 12.94% and a net margin of 14.86%.The business’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 EPS. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. Analysts forecast that HealthEquity will post 2.32 EPS for the current fiscal year.

Insider Transactions at HealthEquity

In other news, EVP Michael Henry Fiore sold 1,781 shares of HealthEquity stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total value of $157,102.01. Following the transaction, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $94.72, for a total value of $142,080.00. Following the completion of the sale, the executive vice president directly owned 73,979 shares in the company, valued at $7,007,290.88. This trade represents a 1.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 17,240 shares of company stock worth $1,640,164. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Hedge funds and other institutional investors have recently modified their holdings of the stock. Xponance Inc. boosted its holdings in HealthEquity by 0.8% in the 3rd quarter. Xponance Inc. now owns 12,265 shares of the company’s stock valued at $1,162,000 after purchasing an additional 102 shares during the period. Nisa Investment Advisors LLC raised its position in shares of HealthEquity by 2.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,787 shares of the company’s stock valued at $397,000 after buying an additional 108 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of HealthEquity by 4.7% in the second quarter. Advisors Asset Management Inc. now owns 2,437 shares of the company’s stock valued at $255,000 after buying an additional 110 shares during the period. Fiduciary Trust Co grew its position in HealthEquity by 3.4% during the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock worth $348,000 after buying an additional 120 shares in the last quarter. Finally, Ieq Capital LLC grew its position in HealthEquity by 4.4% during the first quarter. Ieq Capital LLC now owns 2,945 shares of the company’s stock worth $260,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.